Difference between revisions of "Alvocidib (Flavopiridol)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
Flavonoid alkaloid CDK9 kinase inhibitor | Flavonoid alkaloid CDK9 kinase inhibitor | ||
| + | <br>Route: PO | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 12: | Line 13: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| − | [[Category: | + | [[Category:Oral chemotherapy]] |
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
[[Category:CDK inhibitors]] | [[Category:CDK inhibitors]] | ||
| Line 20: | Line 21: | ||
[[Category:Drugs FDA approved in 2007]] | [[Category:Drugs FDA approved in 2007]] | ||
| + | [[Category:Orphan drug]] | ||
Revision as of 16:06, 28 June 2016
Mechanism of action
Flavonoid alkaloid CDK9 kinase inhibitor
Route: PO
Diseases for which it is used
History of changes in FDA indication
- 4/13/2007: Granted orphan status for treatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.
- 4/23/2014: Granted orphan designation for the treatment of patients with acute myeloid leukemia (AML)